Genomic characterization of patients with de-novo high-volume mCSPC compared to those without
Can circulating tumour DNA guide treatment intensification in de novo metastatic prostate cancer?
ARCHES: OS by high or low disease volume and progression to mHSPC or de novo mHSPC
Enzalutamide + ADT in Men with De Novo mHSPC: The ARCHES Trial
Debulking & Metastatic #ProstateCancer | #MarkScholzMD #AlexScholz #PCRI
Metastatic #ProstateCancer Treatment Case Study | #MarkScholzMD #AlexScholz #PCRI
Triplet Therapy for Metastatic Hormone-sensitive Prostate Cancer
Untreated Metastatic Prostate Cancer - 2021 Prostate Cancer Patient Conference
Subgroups of metastatic hormone-sensitive prostate cancer (mHSPC)
Systemic triple therapy in metastatic hormone-sensitive prostate cancer
Quality of life in treatment of metastatic prostate cancer patients
Oligo-metastatic Prostate Cancer
Bone Metastasis: Diagnosis and Scans | #MarkScholzMD #AlexScholz #PCRI
Stories of Advanced Prostate Cancer Remissions | Ask a Prostate Cancer Expert, Mark Scholz, MD
What Are Advanced Prostate Cancer Treatment Options?
Case 2: High-Volume Versus Low-Volume Metastatic CSPC
Treatment advances in metastatic prostate cancer - Dr. Edmond Kwan
Updates on Management of Metastatic Hormone-Sensitive Prostate Cancer
ADT Resistant Metastatic Prostate Cancer (mCRPC) - 2021 Prostate Cancer Patient Conference
PEACE-1: Abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo mCSPC